FluBlok clinical trials
Also written UMN-0501.
How each study uses FluBlok is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 6
Protein Sciences Corporation (3) · UMN Pharma Inc. (2) · Vaxcyte, Inc. (1) · Duke University (1) · The University of Hong Kong (1) · Centers for Disease Control and Prevention (1) · Sanofi (1) · University of Rochester (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (2) · Fluarix (1) · Fluzone High-Dose (1) · Tadalafil (1) · Poly ICLC (1)
Studies
Open first, then newest update. How each study uses FluBlok is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeCompletedPhase 3Vaxcyte, Inc.NCT07365826Written as Seasonal Influenza Vaccine (SIV) (Flublok)
- Immunogenicity of Influenza VaccinationsCompletedPhase 4Duke UniversityNCT06518577Written as Flublok® (RIV3)
- Dynamics of the Immune Responses to Repeat Influenza Vaccination ExposuresCompletedPhase 4The University of Hong KongNCT04576377Written as FluBlok
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCPCompletedPhase 4Centers for Disease Control and PreventionNCT03722589Written as Flublok
- Recombinant Influenza Vaccination in U.S. Nursing HomesStatus unknownPhase 4Insight Therapeutics, LLCNCT03965195Written as Recombinant Influenza Vaccine
- Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokCompletedPhase 3SanofiNCT00539981Written as FluBlok®
- Comparison of Three Licensed Influenza VaccinesCompletedPhase 4University of RochesterNCT03068949Written as FluBlok
- PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCCCompletedPhase 1Donald T. Weed, MD, FACSNCT02544880Written as Anti-Influenza Vaccine
- Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of AgeCompletedPhase 3Protein Sciences CorporationNCT01825200Written as Flublok
- Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIVCompletedPhase 3Protein Sciences CorporationNCT00539864Written as FluBlok Influenza Vaccination
- Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedPhase 2UMN Pharma Inc.NCT01195038Written as Recombinant Influenza HA Vaccine (H5N1)
- Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedPhase 2UMN Pharma Inc.NCT00980447Written as UMN-0501
- Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsCompletedPhase 2/3Protein Sciences CorporationNCT00328107Written as Influenza Vaccine, recombinant Hemagglutinin